Werewolf Therapeutics, Inc.
HOWLNasdaqHealthcare · Pharmaceutical Preparations · DE · SEC filings ↗ · Compare ⊕
View price & chart on Yahoo Finance ↗Financials
SEC XBRL · annual| FY25 | FY24 | FY23 | FY22 | FY21 | FY20 | |
|---|---|---|---|---|---|---|
| Revenue | — | — | — | — | — | — |
| Operating income | −$60.7M | −$73.6M | −$40.5M | −$56.1M | −$50.1M | −$22.4M |
| Net income | −$60.8M | −$70.5M | −$37.4M | −$53.8M | −$50.0M | −$15.0M |
| Total assets | $69.4M | $126.9M | $174.8M | $160.2M | $179.3M | $96.4M |
| Total liabilities | $44.6M | $53.5M | $63.5M | $37.9M | $26.5M | $7.2M |
| Equity | $24.8M | $73.4M | $111.4M | $122.3M | $152.8M | −$51.9M |
| EPS (diluted) | $-1.33 | $-1.63 | $-1.05 | $-1.86 | $-10.94 | $-28.08 |
| Shares out. | 44.8M | 42.7M | 35.3M | 27.7M | 27.3M | 1.2M |
Reported figures from the company's SEC filings (XBRL). Blank where a line item isn't cleanly tagged — never estimated.
Key ratios
from filings · FY2025- Operating margin
- —
- Net margin
- —
- Return on equity
- −245.2%
- Return on assets
- −87.6%
- Return on capital (ROCE)
- −182.5%
- Liabilities / assets
- 64.3%
- Debt / equity
- 1.80×
- Book value / share
- $0.55
- Revenue growth (YoY)
- —
- Net income growth (YoY)
- —
Computed from the company's own SEC figures — no market price, so these are facts, not a valuation. Book value per share is reported equity ÷ shares; it is not the stock price.
Financial health
forensic scores · FY2025- Altman Z″ (distress)
- -25.50distress
- Accruals / assets
- −0.8%clean
- Piotroski F-Score
- 1/7weak
Altman Z″is a textbook bankruptcy-distress score from book values only (>2.6 safe · 1.1–2.6 grey · <1.1 distress). Accruals = (net income − operating cash flow) ÷ assets; persistently high accruals are an earnings-quality red flag. Beneish M-Scoreis an eight-ratio screen comparing this year with last (M > −1.78 = elevated manipulation-risk screen, not proof). Piotroski F-Scorecounts how many of nine fundamental-health checks pass (shown as passed / applicable; we use operating margin and total liabilities as documented proxies where the exact input isn't XBRL-tagged). Computed from SEC filings — descriptive factors, not advice or a forecast.
Quality score
EDS ScoreOur own multi-factor score from free SEC data — profitability, growth, financial strength, earnings quality, and event/ownership catalysts. No market price and no licensed model: each axis is the share of source-backed checks it passes. Descriptive factors, not advice or a forecast.
Signs
● 1 severe● 1 warning● 1 good- Altman Z″ in the distress zone
- Negative operating cash flow
- Clean earnings (low accruals)
Derived from the company's own SEC figures (fundamentals, forensic scores, filing discipline) — descriptive factors, not advice or a forecast.
Clinical trials
ClinicalTrials.gov · ongoing · next readout first- Phase 1Active Not Recruitingreadout ~2026-07-01Dose Escalation and Expansion Study of WTX-124 as Monotherapy and in Combination With Pembrolizumab (Pembro) in Patients With Selected Advanced or Metastatic Solid Tumors
- Phase 1/2Active Not Recruitingreadout ~2028-08A Phase 1b/2 Multisite Dose-finding and Expansion Study of WTX-330 in Adult Patients With Selected Advanced or Metastatic Solid Tumors or Lymphoma
Interventional studies led by this company. “Readout” is the trial's primary-completion date — an estimate the sponsor reports, not a guarantee.
5%+ owners
SEC Schedule 13D / 13G · last 3 yrs- Ra Capital Management, L.P.Activist (13D)May 14, 2026
- Mpm Bioventures 2014, L.P.Activist (13D)May 12, 2026
- Longwood Fund Iii, L.P.Passive (13G)Feb 11, 2026
- Pfm Health Sciences, LpPassive (13G)Aug 14, 2025
Holders who disclosed a 5%+ stake. 13D signals intent to influence or control; 13G is a passive holding. Latest filing per holder — open it for the exact stake.
Short interest
FINRA · bi-monthly| Settlement | Shares short | Days to cover | Δ vs prior |
|---|---|---|---|
| May 15, 2026 | 667,626 | 1.0 | -8.2% |
| Apr 30, 2026 | 726,859 | 2.4 | -7.7% |
| Apr 15, 2026 | 787,448 | 2.1 | -43.1% |
| Mar 31, 2026 | 1.4M | 5.1 | -1.4% |
| Mar 13, 2026 | 1.4M | 2.8 | -32.3% |
Shares sold short as reported to FINRA. Days-to-cover = short shares ÷ average daily volume — higher means more potential squeeze pressure.
Material events
SEC Form 8-K · most recent- Results of operationsMay 7, 2026
- Results of operationsMar 27, 2026
- Other material eventFeb 24, 2026
- Costs from exit or disposal · Director / officer change · Regulation FD disclosureFeb 13, 2026
- Delisting / listing-standard noticeFeb 6, 2026
- Other material eventDec 18, 2025
- Results of operationsNov 4, 2025
- Delisting / listing-standard noticeOct 6, 2025
Events the company reported on Form 8-K, labelled by the SEC item code it filed under — its own classification, not our interpretation.
Recent SEC filings
All filings ↗Event-driven situations (2)
Spot an error in this record? Report it. Every correction is verified against the source filing before we change anything.